Search News & Press Releases by Tag, Press release news tagged with SignaBlok, Inc.

Press Release March 20, 2025

SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Sepsis, Pulmonary Inflammation and Fibrosis at the Respiratory Innovation Summit and ATS Conference 2025

We will present paradigm-shifting preclinical data on targeting innate inflammation to protect septic mice from death at delayed treatment times as well as to reduce pulmonary inflammation and reverse fibrosis in animal models of lung pathologies.

Read Press Release

Press Release March 19, 2025

SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025

We will present preclinical data on targeting innate inflammation to prevent pancreatic cancer recurrence, improve complete response and survival rate in chemotherapy-treated mice, and overcome cancer resistance in those treated with immunotherapy.

Read Press Release

Press Release April 15, 2015

SignaBlok to Highlight SCHOOL Therapeutic Peptides at the 2015 Essential Protein Engineering Summit

Preclinical studies of novel peptide inhibitors (SCHOOL peptides) will be presented in an oral session. Presentation will highlight company's approach to targeted peptide delivery and support development of programs in oncology, sepsis and arthritis.

Read Press Release

Search News by Tag: SignaBlok, Inc.